Personalized Cancer Treatment for Ovarian Cancer

Chumworathayi, Bandit

doi:10.7314/apjcp.2013.14.3.1661

Cited by 8 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus a detailed understanding of apoptotic mechanisms and factors that can compromise them is critical to design of more potent, specific and effective personalized cancer therapies (Chumworathayi et al, 2013). Futhermore it emanates the necessity to study metformin's chemoadjuvant potential.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Patel

Singh²,

Kumar³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Patel

Singh²,

Kumar³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Moreover, it is well known from neoadjuvant chemotherapy studies that certain breast cancer molecular and/or phenotypic subtypes respond differently to chemotherapy and behave with a different prognosis. In contrast to breast cancer, relatively few reports evaluating the importance of receptor expressions and EOC subtypes exist in the literature and demonstrate contradictory results (Hogdall et al, 2007;Liu et al, 2010;Sinn et al, 2011;Chumworathayi, 2013;Zhao et al, 2013). EGFR expression was also suggested to be related to worse prognosis in a few studies (Skirnisdottir et al, 2001;Noske et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype?

Demir¹,

Yiğit²,

Sadullahoğlu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: We aimed to evaluate the effects of hormone receptor, HER2, and epidermal growth factor receptor (EGFR) expression on epithelial ovarian cancer (EOC) prognosis and investigate whether or not phenotypic subtypes might exist. Materials and Methods: The medical records of 82 patients who were diagnosed with EOC between 2003 and 2012 and treated by platinum-based chemotherapy were retrospectively evaluated. Expression of EGFR, oestrogen (ER), progesterone (PR), and cerbB2 (HER2) receptors were assessed immunohistochemically on paraffin-embedded tissues of these patients. Three phenotypic subtypes were defined according to ER, PR, and HER2 expression and associations of these with EGFR expression, clinicopathologic features, platinum sensitivity, and survival were investigated. Results: When we classified EOC patients into three subtypes, 63.4% had hormone receptor positive (HR(+)) (considering breast cancer subtypes, luminal A), 18.3% had triple negative, and 18.3% had HER2(+) disease. EGFR positivity was observed in 37 patients (45.1%) and was significantly more frequent with advanced disease (p=0.013). However, no significant association with other clinicopathologic features and platinum sensitivity was observed. HER2(+) patients had significantly poorer outcomes than HER2(-) counterparts (triple negative and HR positive patients) (p=0.019). Multivariate analysis demonstrated that the strongest risk factor for death was residual disease after primary surgery. Conclusions: Triple negative EOC may not be an aggressive phenotype as in breast cancer. The HER2 positive EOC has more aggressive behaviour compared to triple negative and HR(+) phenotypes. EGFR expression is more frequent in advanced tumours, but is not related with poorer outcome. Additional ovarian cancer molecular subtyping using gene expression analysis may provide more reliable data.

show abstract

“…Even if using the relatively sensitive drug, such as gemcitabine, doxorubicin, tunicamycin and ifosfamide, the clinical remission rate is only about 10%-20% (Hiss et al, 2007;Chumworathayi, 2013;Pitakkarnkul et al, 2013;Su et al, 2013). Because this group of patients have treated with multiple cycles of chemotherapy, causing hematological and non hematological toxicity accumulation, we chosed only single gemcitabine combined with 125 I-seed implantation treatment as the therapy for patients.…”

Section: Adverse Reactionsmentioning

confidence: 99%

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Yang

Liu²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to explore the efficacy and adverse reactions of CT-guided radioactive 125I-seed implantation treatment combined with chemotherapy for platinum-resistant recurrent ovarian carcinoma. Materials and Methods: From September 2010 to December 2012, 23 patients with platinum-resistant recurrent ovarian carcinoma were enrolled. All the patients refused, could not bear, or were not suitable for surgery. They all had no more than 3 lesions, which were detected and could also be measured by CT. All were clarified as single-lesion or multiple-lesion groups. A total of 41 lesions underwent implantation of from 8 to 106 125I seeds (median=43). Multi-plane implanting was adopted and 125I-seeds of (0.4-0.7)mCi were placed at intervals of (0.5-1.0) cm. After implantation treatment, all patients underwent 4 cycles of chemotherapy with gemcitabine 800 mg/m2 (days 1, 8 and 15). Results: The outcome was evaluated with CT 3 weeks and every 3 months after implantation treatment. After 6 months, the volume of 32 out of 41 lesions (78.0%) was reduced at least 30%, within which 9 lesions completely disappeared(22.0%). Complete response was observed in 7 cases (30.4%), with a partial response in 4 cases (17.4%),4 cases stable(17.4%)and 8 cases showing progression (34.8%). The total clinical remission rate was 47.8% (11/23). The clinical remission rate was 77.8% (7/9) in the single-lesion group and 28.6% (4/14) in the multiple-lesion group with a significant difference between the two(P=0.036). The common side effects observed were mild gastrointestinal reactions. Conclusions: 125I-seed implantation combined with chemotherapy applies an effective way in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma with the advantages of high local control rates, good short-term effects, little trauma and less side effects.

show abstract

Personalized Cancer Treatment for Ovarian Cancer

Cited by 8 publications

References 11 publications

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype?

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Contact Info

Product

Resources

About